About Mounjaro (tirzepatide) in Ireland
Mounjaro is the brand name for tirzepatide, a groundbreaking once-weekly injectable medication originally developed to treat type 2 diabetes. In recent years it has also been authorised in Europe for chronic weight management in adults with obesity or overweight who meet certain criteria. Mounjaro works by mimicking two natural gut hormones to regulate appetite and blood sugar, helping people feel fuller with less food. It is a prescription-only medicine that, combined with a healthy diet and exercise, can lead to dramatic weight-loss results for eligible patients.
In Ireland, Mounjaro has quickly gained attention as a potent new option for weight loss. It is now available under medical supervision for adults with a high body mass index (BMI) or weight-related health issues, following its approval by the European authorities in 2024. This guide explains what Mounjaro is, how it compares to treatments like Ozempic and Wegovy, who can use it, how to access it in Ireland, the costs involved, dosing schedules, potential side effects, and the results you might expect.
What is Mounjaro and how does it work?
Mounjaro contains tirzepatide, a first-in-class dual hormone receptor agonist. It activates two key hormones involved in blood sugar control and appetite: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By targeting both receptors, tirzepatide helps to:
- Suppress appetite and cravings — it signals the brain to reduce hunger, helping you feel full sooner and for longer.
- Slow gastric emptying — it slows how quickly your stomach empties after eating, prolonging fullness after meals.
- Improve metabolic control — it increases insulin release and sensitivity when needed, helping keep blood sugar stable, which may also aid weight management.
Through these dual actions, Mounjaro helps reduce calorie intake and improve control over eating habits. In essence it combines the benefits of GLP-1 agonist medications (like semaglutide in Ozempic and Wegovy) with the added action of GIP agonism for potentially greater effect — which is why many consider it a significant advancement in weight-loss treatment.
Mounjaro vs Ozempic vs Wegovy: how does tirzepatide compare?
It is natural to compare Mounjaro with other popular weight-loss medications such as Ozempic and Wegovy, which contain semaglutide (a GLP-1 agonist). All are weekly injections that help with weight loss by curbing appetite, but there are key differences:
- Active ingredient: Mounjaro is tirzepatide, a dual GLP-1/GIP agonist, whereas Ozempic and Wegovy use semaglutide, a GLP-1 agonist only. Tirzepatide's dual action may enhance its appetite-suppressing and metabolic effects.
- Weight-loss efficacy: Clinical trials suggest Mounjaro can produce greater weight loss on average. Patients on the highest dose (15 mg) lost around 21–22.5% of their body weight over ~72 weeks, whereas trials of semaglutide (Wegovy 2.4 mg) showed about 15% average weight loss in a similar period.
- Treatment indications: Wegovy is approved specifically for weight management; Ozempic is officially for type 2 diabetes (often used off-label for weight loss). Mounjaro is approved in the EU for both — type 2 diabetes and, as of 2024, weight loss in qualifying patients.
- Dosing: All three are weekly subcutaneous injections (abdomen, thigh or upper arm). Mounjaro comes in multiple strengths (2.5 mg up to 15 mg) titrated over time, whereas Wegovy goes up to 2.4 mg weekly and Ozempic up to 1–2 mg.
- Side-effect profile: The types of side effects are similar since both act on GLP-1 receptors. Nausea and stomach upset are common with all.
In summary, Mounjaro offers an even more powerful option compared with single-hormone GLP-1 medications. Many patients who have plateaued on Ozempic or Wegovy are interested in it for its potentially greater weight reduction. That said, Wegovy and Ozempic are highly effective too, and any of these should only be used if appropriate for your situation — a doctor can help determine which option, if any, is best for you.
Who is eligible for Mounjaro in Ireland?
Mounjaro is generally prescribed for weight loss in adults who meet specific BMI criteria. In Ireland (consistent with EU approval), you may be eligible if:
- Your BMI is 30 or above (classified as obese), or
- Your BMI is 27 or above and you have at least one significant weight-related health condition (such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea).
If you have type 2 diabetes with suboptimal control, you may also qualify on that basis. Mounjaro is intended for adults (18+) and is not used in children or during pregnancy or breastfeeding.
Suitability and contraindications: before starting, a clinician will screen for conditions that would make it unsafe. You should not use Mounjaro if you have a personal or family history of medullary thyroid carcinoma or a genetic endocrine tumour syndrome. People with a history of pancreatitis are typically cautioned against it, as GLP-1/GIP therapies may increase pancreatitis risk in susceptible individuals. Severe digestive or gallbladder disease should also be discussed with your doctor.
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →How to get a Mounjaro prescription in Ireland
Doctor or specialist: the traditional route is to speak with your GP or an obesity specialist. If they agree you meet the criteria, they can write a private prescription that you take to a pharmacy stocking Mounjaro. Ireland's public health system does not currently subsidise Mounjaro for weight loss, so this is paid out of pocket.
Online weight-loss clinics: a convenient option is a regulated online service such as Slimbr. Slimbr offers access to Mounjaro through an online consultation with a licensed practitioner. You start with a quick free eligibility quiz; a Slimbr clinician then reviews your health information (including BMI and any conditions) to determine if Mounjaro is appropriate. If you qualify, Slimbr's medical team can provide a prescription and guide you on obtaining the medication through a partner pharmacy — completing the assessment from home, with no long waits or multiple clinic visits.
Mounjaro dosage and schedule
A key feature of Mounjaro is its dose-escalation schedule. You do not start at the highest dose; the medication is introduced gradually so your body can adjust and side effects are minimised. The typical schedule for weight loss is:
- Starting dose – 2.5 mg: once weekly for the first 4 weeks. This low "getting used to it" dose may not cause much weight loss; its purpose is to let your body adapt.
- 5 mg: after 4 weeks, if tolerated, the dose increases to 5 mg weekly for at least another 4 weeks.
- 7.5 mg: typically weeks 9–12, if needed and if side effects are manageable.
- 10 mg: many patients move up around weeks 13–16.
- 12.5 mg: around weeks 17–20.
- Maintenance – 15 mg: from about week 21 onward, the target maximum dose. Not everyone needs to go this high — some achieve their goals or prefer to stay at an intermediate dose.
This stepwise titration (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) usually allows at least 4 weeks on each level. Your provider monitors progress and side effects at each stage and adjusts the pace to find the dose that balances maximum weight loss with minimal side effects.
Administration: Mounjaro comes in a pre-filled pen for subcutaneous injection, similar to an insulin pen. Inject once a week on the same day for consistency, rotating between abdomen, thigh and upper arm. Store unused pens in the refrigerator (2–8°C) and do not freeze them; each pen is single-use and should be disposed of in a sharps container.
What results can you expect on Mounjaro?
- Clinical trial averages: in the SURMOUNT-1 trial of over 2,500 adults without diabetes, tirzepatide helped patients lose an average of about 15% of body weight at mid-range doses, and up to 22.5% on the 15 mg dose over 72 weeks. For someone weighing 100 kg, that is roughly 15–22 kg.
- Most reach 5–10% loss: over 9 in 10 patients lost at least 5% of their weight, and about 8 in 10 lost 10% or more. Losing just 5–10% is often enough to significantly improve blood sugar, blood pressure and other health markers.
- Rapid early loss: many patients see noticeable changes after 2–3 months, with around 4% weight reduction in the first month on average.
- One-year outcomes: approaching 52 weeks, data often shows 15% or more average loss for those who stay on therapy and tolerate higher doses, with some losing 20%+.
- Long-term management: medication is one tool. The best results come with improvements in diet and exercise, which also help maintain weight loss if Mounjaro is ever stopped.
Beyond weight loss: because tirzepatide began as a diabetes medication, it can greatly improve blood sugar control and insulin sensitivity. Patients have also seen improvements in blood pressure and cholesterol, and there is evidence it can help conditions like fatty liver disease and sleep apnoea. Many report non-scale victories such as more energy, better sleep, reduced joint pain and improved confidence.
Potential side effects of Mounjaro
Like any medication, Mounjaro can cause side effects — most relate to the digestive system, which is part of how it helps cause weight loss. For many people these are manageable and tend to improve over time as the body adapts. Common side effects include:
- Nausea — the most frequently reported effect, especially when starting or increasing the dose (about 1 in 5 people). Smaller, blander meals help, and it usually eases over the following weeks.
- Digestive upset — vomiting, diarrhoea or stomach cramping, especially during dose increases (reported in up to ~10%). Staying hydrated and avoiding greasy overeating help.
- Constipation — some experience slower bowel movements; high-fibre foods, plenty of water and, if needed, mild laxatives help.
- Indigestion and acid reflux — due to slower gastric emptying; smaller, frequent meals and not lying down straight after eating help.
- Loss of appetite — an intended effect, but make sure you still get balanced nutrition. If you have diabetes, monitor your blood sugar carefully.
- Fatigue or dizziness — usually improves as the body adjusts; avoid over-restricting your diet.
- Injection-site reactions — mild redness, itching or tenderness; rotating sites each week prevents irritation.
Most side effects are mild to moderate and occur more often at the initial dose or when increasing. This is exactly why dosing is gradual. If any side effect is persistent or troublesome, tell your healthcare provider — they may recommend supportive treatment or adjust your dose.
Serious side effects are rare. Seek medical attention for severe abdominal pain that will not go away (especially if it radiates to your back), as this could signal pancreatitis or gallbladder issues, or for persistent vomiting and signs of dehydration. In trials only about 3% of people stopped Mounjaro due to side effects. The European Medicines Agency concluded its benefits outweigh the risks for approved patients — provided you remain under medical supervision with routine check-ins.
Mounjaro price in Ireland — how much does it cost?
Weight-loss injections like Mounjaro are expensive, as they are brand-name medicines without generic alternatives yet. In Ireland the cost depends on the dose strength, priced per pre-filled pen (about a month's supply). As of 2025, approximate monthly prices from Irish pharmacies are:
- €275–€300 for the 2.5 mg starter dose,
- €350–€375 for 5 mg,
- €450–€480 for 7.5 mg or 10 mg, and
- €570–€600 for 12.5 mg or 15 mg.
As your dose increases, the monthly cost rises. Insurance and the public health service (HSE) do not currently cover Mounjaro for weight loss, so patients bear the full cost out of pocket. On top of the medication there may be a consultation fee for the prescribing service. With Slimbr the initial quiz is free, with transparent pricing for the clinician review and ongoing support if you proceed (you still pay the pharmacy for the medication separately).
Due to high demand there have been periodic shortages of weight-loss injections globally, and prices can fluctuate. Only obtain Mounjaro through legitimate pharmacies with a valid prescription — never from unofficial sources offering it without one, which could be scams or counterfeits. Slimbr or your doctor will guide you to get the medicine safely and legally.
Conclusion
Mounjaro (tirzepatide) represents an exciting advancement in obesity treatment, offering significant weight loss to those who have struggled with traditional methods alone. It is not a quick fix — it requires commitment to a healthier lifestyle and careful medical oversight — but it has helped patients lose 20% or more of their weight in clinical studies, far above older therapies. You will need to consider the cost, weekly injections and potential side effects, and it is generally a long-term treatment.
The first step is to find out if you are a candidate. Take Slimbr's free online assessment → and, if appropriate, our weight-loss professionals can guide you through a personalised plan with the support and monitoring to achieve meaningful, lasting results.
